14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CING vs DRMA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Cingulate Inc. (CING) is the stronger overall head-to-head candidate over Dermata Therapeutics, Inc. (DRMA) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). CING carries a Unified Composite Score of 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin), whereas DRMA carries 43.8/100 (HOLD) at $0.58 (N/M Forward P/E, -13082.3% operating margin).
Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.8); meanwhile DRMA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs DRMA. Trailing 12-month operating profitability (CING 0.0% vs DRMA -13082.3%) and valuation multiples (CING N/M vs DRMA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.1M market capitalization and -13082.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CING vs DRMA Key Questions & Quantitative Answers
As of Nov 17, 2026, Cingulate Inc. (CING) is the stronger overall head-to-head candidate over Dermata Therapeutics, Inc. (DRMA) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). CING carries a Unified Composite Score of 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin), whereas DRMA carries 43.8/100 (HOLD) at $0.58 (N/M Forward P/E, -13082.3% operating margin). Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.8); meanwhile DRMA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CING and DRMA split Growth & Scale metrics: CING posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DRMA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $74,137 TTM revenue (54.1% gross margin, -13082.3% operating margin). On trailing 12-month operating scale, CING generates N/A in USD-normalized revenue versus $74,137 for DRMA. In operating R&D and SG&A reinvestment, CING deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DRMA.
DRMA screens cheaper on headline valuation multiples. CING trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DRMA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 41.3x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CING (-198.7% ROE) versus DRMA (-241.5% ROE) capital efficiency.
In options market volatility and institutional positioning, CING carries 111.1% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.13β · 117% Vol realized risk). By comparison, DRMA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.10β · 112% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.